Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Cited by (1,000)

Items 301–400 of 1,000

1. Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites
   Florian Wittlinger, David E. Heppner, Ciric To, Marcel Günther, Bo Hee Shin, Jaimin K. Rana, Anna M. Schmoker, Tyler S. Beyett, Lena M. Berger, Benedict‐Tilman Berger et al. · 2021 · Journal of Medicinal Chemistry
2. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives
   Hassan M. Shallal, Wade A. Russu · 2011 · European Journal of Medicinal Chemistry
3. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation
   Yi Shen, Dongfang Tang, Ruyong Yao, Mingzhao Wang, Yongjie Wang, Yasai Yao, Xiaoxiao Li, Haiping Zhang · 2013 · Medical Oncology
4. Utilizing protein structure to identify non-random somatic mutations
   Gregory A Ryslik, Yuwei Cheng, Kei-Hoi Cheung, Yorgo Modis, Hongyu Zhao · 2013 · BMC Bioinformatics
5. 4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase
   Emily J. Hanan, Matt Baumgardner, Marian C. Bryan, Yuan Chen, Charles W. Eigenbrot, Peter W. Fan, Xiao‐Hui Gu, Hank La, Shiva Malek, Hans E. Purkey et al. · 2015 · Bioorganic & Medicinal Chemistry Letters
6. Detection EGFR exon 19 status of lung cancer patients by DNA electrochemical biosensor
   Xiongwei Xu, Xiuhua Weng, Changlian Wang, Wei-Wei Lin, Ai‐Lin Liu, Wei Chen, Xinhua Lin · 2016 · Biosensors and Bioelectronics
7. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
   Nele Van Der Steen, Chiara Caparello, Christian Diego Rolfo, Patrick Pauwels, Godefridus J. Peters, Elisa Giovannetti · 2016 · OncoTargets and Therapy
8. Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase
   Marc Hoemberger, Warintra Pitsawong, Dorothee Kern · 2020 · Proceedings of the National Academy of Sciences
9. Synthesis and biological evaluation of novel [1,2,3]triazolo-pyrrolo[1,2-a]pyrido[4,3-d]pyrimidines as EGFR targeting anticancer agents
   Sandhya Rani Bandi, Natte Kavitha, Satheesh Kumar Nukala, Narasimha Swamy Thirukovela, Ravinder Manchal, Rambabu Palabindela, Sirassu Narsimha · 2022 · Journal of Molecular Structure
10. Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
    Silvia La Monica, Cristina Caffarra, Francesca Saccani, Elena Galvani, Maricla Galetti, Claudia Fumarola, Mara A. Bonelli, Andrea Cavazzoni, Daniele Cretella, Rita Sirangelo et al. · 2013 · PLoS ONE
11. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors
    Shuang Lü, Wei Zheng, Liyun Ji, Qun Luo, Xiang Hao, Xianchan Li, Fuyi Wang · 2012 · European Journal of Medicinal Chemistry
12. Receptor-Based Virtual Screening of EGFR Kinase Inhibitors from the NCI Diversity Database
    Kiattawee Choowongkomon, Orathai Sawatdichaikul, Napat Songtawee, Jumras P. Limtrakul · 2010 · Molecules
13. Toward a More Precise Future for Oncology
    Murciano-Goroff, Yonina R., Taylor, Barry S., Hyman, David M., Schram, Alison M. · 2020 · Cancer Cell
14. New coumarin derivative with potential antioxidant activity: Synthesis, DNA binding and in silico studies (Docking, MD, ADMET)
    Serda Kecel‐Gunduz, Yasemin Budama‐Kilinc, Bilge Bıçak, Bahar Gök, Burcu Belmen, Feray Aydoğan, Çiğdem Yolaçan · 2022 · Arabian Journal of Chemistry
15. Structural and Functional Analysis of G Protein–Coupled Receptor Kinase Inhibition by Paroxetine and a Rationally Designed Analog
    Kristoff T. Homan, Emily Wu, Michael W. Wilson, Puja Singh, Scott D. Larsen, John J. G. Tesmer · 2013 · Molecular Pharmacology
16. Chapter Six - The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling
    Alexia Conte, Sara Sigismund · 2016 · Progress in molecular biology and translational science
17. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations
    Hanako Hasegawa, Hiroyuki Yasuda, Junko Hamamoto, Keita Masuzawa, Tetsuo Tani, Shigenari Nukaga, Toshiyuki Hirano, Keigo Kobayashi, Tadashi Manabe, Hideki Terai et al. · 2018 · Lung Cancer
18. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations
    Shinnosuke Ikemura, Hiroyuki Yasuda, Shingo Matsumoto, Mayumi Kamada, Junko Hamamoto, Keita Masuzawa, Keigo Kobayashi, Tadashi Manabe, Daisuke Arai, Ichiro Nakachi et al. · 2019 · Proceedings of the National Academy of Sciences
19. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors
    Samar Mowafy, Nahla A. Farag, Khaled A. M. Abouzid · 2012 · European Journal of Medicinal Chemistry
20. The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors
    Rama Krishna Kancha, Christian Peschel, Justus Duyster · 2011 · Journal of Thoracic Oncology
21. Conformation-Specific Effects of Raf Kinase Inhibitors
    Xiaolun Wang, Joseph Y. Kim · 2012 · Journal of Medicinal Chemistry
22. EGFR, the Lazarus target for precision oncology in glioblastoma
    Benjamin Lin, Julia K. Ziebro, Erin Smithberger, Kasey Skinner, Eva Zhao, Timothy Francis Cloughesy, Zev A. Binder, Donald M. O’Rourke, David A. Nathanson, Frank B. Furnari et al. · 2022 · Neuro-Oncology
23. Epidermal growth factor receptor inhibitors in oncology
    Igor Vivanco, Ingo K. Mellinghoff · 2010 · Current Opinion in Oncology
24. Computational Modeling of Structurally Conserved Cancer Mutations in the RET and MET Kinases: The Impact on Protein Structure, Dynamics, and Stability
    Anshuman Dixit, Ali Torkamani, Nicholas J. Schork, Gennady M. Verkhivker · 2009 · Biophysical Journal
25. Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket
    Srinivasaraghavan Kannan, Gireedhar Venkatachalam, Hong Hwa Lim, Uttam Surana, Chandra Shekhar Verma · 2018 · Chemical Science
26. Crystal structure, Hirshfeld surface and DFT computations, along with molecular docking investigations of a new pyrazole as a tyrosine kinase inhibitor
    Mohammed Chalkha, Anouar Ameziane El Hassani, Asmae Nakkabi, Burak Tüzün, Mohamed Bakhouch, Adil Touimi Benjelloun, M. Sfaira, Mohamed Saadi, Lahcen El Ammari, Mohamed El Yazidi · 2022 · Journal of Molecular Structure
27. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
    Valentina Pirazzoli, Deborah O. Ayeni, Catherine Belle Meador, Basavaraju G. Sanganahalli, Fahmeed Hyder, Elisa de Stanchina, Sarah B. Goldberg, William J. Pao, Katerina A. Politi · 2015 · Clinical Cancer Research
28. Effect of Phosphorylation on EGFR Dimer Stability Probed by Single-Molecule Dynamics and FRET/FLIM
    Oana Coban, Laura C. Zanetti-Domingues, Daniel R. Matthews, Daniel J. Rolfe, Gregory E. Weitsman, Paul R. Barber, Jody Barbeau, Viviane Devauges, Florian Kampmeier, Martyn Winn et al. · 2015 · Biophysical Journal
29. Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
    Stephen Michael Rothenberg, Kyle Concannon, Sarah J. Cullen, Gaylor Boulay, Alexa B. Turke, Anthony C. Faber, Elizabeth L. Lockerman, Miguel N. Rivera, Jeffrey A. Engelman, Shyamala Maheswaran et al. · 2015 · eLife
30. EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src
    Michael J Begley, Cai‐Hong Yun, Christina Anja Gewinner, John M. Asara, Jared Lee Johnson, Anthony J. Coyle, Michael J. Eck, Irina Apostolou, Lewis C. Cantley · 2015 · Nature Structural & Molecular Biology
31. Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
    Monia Hossam, Deena S. Lasheen, Khaled A. M. Abouzid · 2016 · Archiv der Pharmazie
32. Kinases inhibitors in lung cancer: From benchside to bedside
    Pankaj Kumar Singh, Harpreet Singh, Om Silakari · 2016 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
33. Structural pharmacological studies on EGFR T790M/C797S
    Lulu Kong, Rui Ma, Ming-Yu Yao, Xiao-E Yan, Sujie Zhu, Peng Zhao, Cai‐Hong Yun · 2017 · Biochemical and Biophysical Research Communications
34. Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments
    Wen‐Qian Li, Jiuwei Cui · 2020 · Journal of Cancer Research and Clinical Oncology
35. Anti-proliferative action, molecular investigation and computational studies of novel fused heterocyclic cellulosic compounds on human cancer cells
    Ghada H. Elsayed, Sawsan Dacrory, Asmaa Mahmoud Fahim · 2022 · International Journal of Biological Macromolecules
36. The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation?
    Chung‐Jung Tsai, Ruth Nussinov · 2014 · Physical Chemistry Chemical Physics
37. Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
    Haizhen A. Zhong, J. Phillip Bowen · 2011 · Current Topics in Medicinal Chemistry
38. Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis
    Yasmin A. Kadry, Jia-Ying Lloyd Lee, Eric S. Witze · 2021 · Open Biology
39. Designing of kinase hinge binders: A medicinal chemistry perspective
    Vikas Sharma, Mohit Gupta · 2022 · Chemical Biology & Drug Design
40. KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming
    Nicholas H. Juul, Jung-Ki Yoon, Marina C. Martinez, Neha Rishi, Yana I. Kazadaeva, Maurizio Morri, Norma F Neff, Winston Trope, Joseph B. Shrager, Rahul Sinha et al. · 2023 · Nature
41. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
    Maicol Mancini, Yosef Yarden · 2015 · Seminars in Cell and Developmental Biology
42. The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer
    Eunice Lee Kwak · 2011 · The Oncologist
43. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
    Yosef Yarden, Deric L. Wheeler · 2014 · Springer eBooks
44. Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis
    Martiniano Bello · 2018 · International Journal of Biological Macromolecules
45. Structural basis of mutant-selectivity and drug-resistance related to CO-1686
    Yan, Xiao-E, Zhu, Su-Jie, Liang, Ling, Zhao, Peng, Choi, Hwan Geun, Yun, Cai-Hong · 2017 · Oncotarget
46. Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds
    Samiksha Katiyar, Irina Kufareva, Ranjan Behera, Sarah M. Thomas, Yuko Ogata, Michael P. Pollastri, Ruben A Abagyan, Kojo Mensa‐Wilmot · 2013 · PLoS ONE
47. The epidermal growth factor receptor (EGRF) in lung cancer
    Enric Carcereny, Teresa Morán, Laia Capdevila, Sara Cros, Laia Vilà, María de los Llanos Gil, Jordi Remón, Rafael Rosell · 2015 · Translational Respiratory Medicine
48. EGFR genomic alterations in cancer prognostic and predictive values
    Antonio Dello Russo · 2011 · Frontiers in Bioscience-Elite
49. Synthesis, biological evaluation and molecular modeling study of [1,2,4]-Triazolo[4,3-c]quinazolines: New class of EGFR-TK inhibitors
    Wafaa A Ewes, Mohammad A. Elmorsy, Shahenda M. El‐Messery, Magda N.A. Nasr · 2020 · Bioorganic & Medicinal Chemistry
50. Quinoline conjugated 2-azetidinone derivatives as prospective anti-breast cancer agents: In vitro antiproliferative and anti-EGFR activities, molecular docking and in-silico drug likeliness studies
    K. Govindarao, N. Srinivasan, R. Suresh, R.K. Raheja, Sivakumar Annadurai, Richie Rashmin Bhandare, AFZAL BASHA SHAIK · 2022 · Journal of Saudi Chemical Society
51. Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma
    Shigeyuki Ozawa, Yukio Kato, Shin Ito, Reika Komori, Naoto Shiiki, Keiichi Tsukinoki, Satoru Ozono, Yojiro Maehata, Takahide Taguchi, Yukari Imagawa et al. · 2009 · Cancer Science
52. Temporal Resolution of Autophosphorylation for Normal and Oncogenic Forms of EGFR and Differential Effects of Gefitinib
    Youngjoo Kim, Zhimin Li, Mihaela M. Apetri, BeiBei Luo, Jeffrey E. Settleman, Karen S. Anderson · 2012 · Biochemistry
53. New series of benzothiazole and pyrimido[2,1-b]benzothiazole derivatives: synthesis, antitumor activity, EGFR tyrosine kinase inhibitory activity and molecular modeling studies
    Moustafa Tarek Gabr, Nadia S. El‐Gohary, Eman R. El‐Bendary, Mohamed M. El‐Kerdawy · 2014 · Medicinal Chemistry Research
54. Quantum chemical calculations on sparfloxacin and boron complexes
    Ayhan Üngördü, Koray Sayın · 2019 · Chemical Physics Letters
55. Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations
    Jun Wang, Daniel Lam, Jeffrey Yang, Longqin Hu · 2022 · Medicinal Chemistry Research
56. Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion
    Caterina Carmi, Alessio Lodola, Silvia Rivara, Federica Vacondio, Andrea Cavazzoni, Roberta R Alfieri, Andrea Ardizzoni, P. G. Petronini, Marco Mor · 2011 · Mini-Reviews in Medicinal Chemistry
57. Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation
    Shunsuke Okumura, Takaaki Sasaki, Yoshinori Minami, Yoshinobu Ohsaki · 2011 · Journal of Thoracic Oncology
58. Structural insights into drug development strategy targeting EGFR T790M/C797S
    Sujie Zhu, Peng Zhao, Jiao Yang, Rui Ma, Xiao-E Yan, Shengyong Yang, Jingwen Yang, Cai‐Hong Yun · 2018 · Oncotarget
59. Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors
    Yuan‐Yuan Hei, Ying H. Shen, Jin Wang, Hao Zhang, Hongyi Zhao, Minhang Xin, Yong‐Xiao Cao, Yan Li, San‐Qi Zhang · 2018 · Bioorganic & Medicinal Chemistry
60. Pharmacophore modeling, 3D-QSAR, docking and ADME prediction of quinazoline based EGFR inhibitors
    Garima Verma, Mohemmed Faraz Khan, Wasim Akhtar, Mohammad Mumtaz Alam, Mymoona Akhter, Ozair Alam, S. S. Hasan, Mohammad Shaquiquzzaman · 2016 · Arabian Journal of Chemistry
61. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
    Venugopalan, Abhilash, Lee, Min-Jung, Niu, Gang, Medina-Echeverz, José, Tomita, Yusuke, Lizak, Martin J., Cultraro, Constance M., Simpson, Robert Mark, Chen, Xiaoyuan, Trepel, Jane B. et al. · 2016 · Oncotarget
62. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors
    Xun Ji, Ting Peng, Xu Zhang, Jian Li, Wei Yang, Linjiang Tong, Rong Qu, Hualiang Jiang, Jian Ding, Hua Xie et al. · 2014 · Bioorganic & Medicinal Chemistry
63. A growing family: Adding mutated Erbb4 as a novel cancer target
    Udo Rudloff, Yardena Samuels · 2010 · Cell Cycle
64. QSAR-Based Models for Designing Quinazoline/Imidazothiazoles/Pyrazolopyrimidines Based Inhibitors against Wild and Mutant EGFR
    Jagat Singh Chauhan, Sandeep Kumar Dhanda, Deepak Singla, Subhash Mohan Agarwal, Gajendra P. S. Raghava · 2014 · PLoS ONE
65. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
    Xinghao Ai, Yingjia Sun, Haidong Wang, Shun Lü · 2014 · Amino Acids
66. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
    Luigi Formisano, Valentina D'Amato, Alberto Servetto, Simona Brillante, Lucia Raimondo, Concetta Di Mauro, Roberta Marciano, Roberta Clara Orsini, Sandro Cosconati, Antonio Randazzo et al. · 2015 · Oncotarget
67. Predicting Kinase Selectivity Profiles Using Free-Wilson QSAR Analysis
    Simone Sciabola, Robert V. Stanton, Sarah Wittkopp, Scott A. Wildman, Deborah J. Moshinsky, Shobha Potluri, Hualin Simon Xi · 2008 · Journal of Chemical Information and Modeling
68. A structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer
    David E. Heppner, Michael J. Eck · 2021 · Protein Science
69. Structure-Based Network Analysis of Activation Mechanisms in the ErbB Family of Receptor Tyrosine Kinases: The Regulatory Spine Residues Are Global Mediators of Structural Stability and Allosteric Interactions
    Kevin A. James, Gennady M. Verkhivker · 2014 · PLoS ONE
70. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant
    Xuemei Qin, Zhipeng Li, Leifu Yang, Peng Liu, Liming Hu, Cheng‐Chu Zeng, Zhiyong Pan · 2016 · Bioorganic & Medicinal Chemistry
71. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non–Small Cell Lung Cancer
    Toshiyuki Hirano, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Tatsuya Niimi, Shinya Mimasu, Hideki Sakagami et al. · 2018 · Molecular Cancer Therapeutics
72. Identification of new candidate drugs for lung cancer using chemical–chemical interactions, chemical–protein interactions and a K-means clustering algorithm
    Jing Lu, Lei Chen, Jun Yin, Tao Huang, Yi Bi, Xiangyin Kong, Mingyue Zheng, Yu‐Dong Cai · 2016 · Journal of Biomolecular Structure and Dynamics
73. A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer
    Delora Baptista, Pedro Gabriel Ferreira, Miguel Rocha · 2023 · PLoS Computational Biology
74. Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma
    Jiaqi Liang, Guoshu Bi, Qihai Sui, Guangyin Zhao, Huan Zhang, Yunyi Bian, Zhencong Chen, Yiwei Huang, Junjie Xi, Yu Shi et al. · 2024 · Cell Reports
75. The antitumor effects of herbal medicine Triphala on oral cancer by inactivating PI3K/Akt signaling pathway: based on the network pharmacology, molecular docking, in vitro and in vivo experimental validation
    Shaonan Hu, Simin Li, Yuzhen Xu, Xiuhong Huang, Zhaoyi Mai, Yuanxin Chen, Hui Xiao, Wanchen Ning, Sebastian Gaus, Vuk Savković et al. · 2024 · Phytomedicine
76. Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry
    Takeshi Harada, Ariel López-Chávez, Liqiang Xi, Mark A. Raffeld, Y Wang, Giuseppe Giaccone · 2010 · Oncogene
77. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors
    Xuemei Qin, Yongjuan Lv, Peng Liu, Zhipeng Li, Liming Hu, Cheng‐Chu Zeng, Leifu Yang · 2016 · Bioorganic & Medicinal Chemistry Letters
78. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
    Masato Chiba, Yosuke Togashi, Eri Bannno, Yoshihisa Kobayashi, Yu Nakamura, Hidetoshi Hayashi, Masato Terashima, Marco Antonio De Velasco, Kazuko Sakai, Yoshihiko Fujita et al. · 2017 · BMC Cancer
79. Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
    Shi, Jinpeng, Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China, Yang, Hui, Jiang, Tao, Li, Xuefei, Zhao, Chao, Zhang, Limin, Zhao, Sha, Liu, Xiaozhen, Jia, Yijun et al. · 2017 · Chinese Journal of Cancer Research
80. Synthesis, characterization, molecular modeling against EGFR target and ADME/T analysis of novel purine derivatives of sulfonamides
    M. A. Bhat, Burak Tüzün, Nawaf A. Alsaif, Azmat Ali Khan, Ahmed Mohamed Naglah · 2022 · Journal of Molecular Structure
81. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines
    Svein Jacob Kaspersen, Christopher Sørum, Veronica Willassen, Erik Fuglseth, Eli Kjøbli, Geir Bjørkøy, Eirik Sundby, Bård Helge Hoff · 2011 · European Journal of Medicinal Chemistry
82. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?
    Vijay Agarwal, MJ Lind, Lynn Cawkwell · 2010 · Cancer Treatment Reviews
83. Bi-Directional SIFT Predicts a Subset of Activating Mutations
    William Lee, Yan Zhang, Kiran Mukhyala, Robert A. Lazarus, Zemin Zhang · 2009 · PLoS ONE
84. Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma WithEGFR-Activating Mutations
    Shinsheng Yuan, Sung‐Liang Yu, Hsuan‐Yu Chen, Yi‐Chiung Hsu, Kang‐Yi Su, Huei‐Wen Chen, Chih‐Yi Chen, Chong‐Jen Yu, Jin‐Yuan Shih, Yih‐Leong Chang et al. · 2011 · Journal of Clinical Oncology
85. Structure-Functional Prediction and Analysis of Cancer Mutation Effects in Protein Kinases
    Anshuman Dixit, Gennady M. Verkhivker · 2014 · Computational and Mathematical Methods in Medicine
86. Pyrimido[4,5‐d]pyrimidin‐4(1H)‐one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants
    Tianfeng Xu, Lianwen Zhang, Shilin Xu, Chao‐Yie Yang, Jinfeng Luo, Fang Ding, Xiaoyun Lu, Yingxue Liu, Zhengchao Tu, Shiliang Li et al. · 2013 · Angewandte Chemie International Edition
87. Processing Temporal Growth Factor Patterns by an Epidermal Growth Factor Receptor Network Dynamically Established in Space
    Aneta Koseska, Philippe I. H. Bastiaens · 2020 · Annual Review of Cell and Developmental Biology
88. Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19
    Jennifer Alisa Amrhein, Tyler S. Beyett, William W. Feng, Andreas Krämer, Janik Weckesser, Ilse K. Schaeffner, Jaimin K. Rana, Pasi Antero Janne, Michael J. Eck, Stefan Knapp et al. · 2022 · Journal of Medicinal Chemistry
89. Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors
    Kristopher W. Hoyt, Daniel A. Urul, Blessing C. Ogboo, Florian Wittlinger, Stefan Laufer, Erik Schaefer, Earl W. May, David E. Heppner · 2023 · Journal of Medicinal Chemistry
90. Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs
    Shunzhou Wan, Peter V. Coveney · 2011 · Journal of The Royal Society Interface
91. Emission Tuning of Fluorescent Kinase Inhibitors: Conjugation Length and Substituent Effects
    Jyothi Dhuguru, Wenjun Liu, Walter G. Gonzalez, W. Michael Babinchak, Jaroslava Mikšovská, Ralf Landgraf, James N. Wilson · 2014 · The Journal of Organic Chemistry
92. Clinical mutational profiling of 1006 lung cancers by next generation sequencing
    Peter Bela Illei, Deborah Belchis, Li‐Hui Tseng, Doreen N. Nguyen, Federico De Marchi, Lisa M. Haley, Stacy L. Riel, Katie F. Beierl, Gang Zheng, Julie Renee Brahmer et al. · 2017 · Oncotarget
93. The significance of gene mutations across eight major cancer types
    Prosenjit Paul, Arup Kumar Malakar, Supriyo Chakraborty · 2019 · Mutation Research/Reviews in Mutation Research
94. EGFR inhibition in non-small cell lung cancer: current evidence and future directions
    Alexander Chi, Scot C. Remick, William W. Tse · 2013 · Biomarker Research
95. Conformational regulation of the EGFR kinase core by the juxtamembrane and C‐terminal tail: A molecular dynamics study
    Morad Mustafa, Amar Mirza, Natarajan Kannan · 2010 · Proteins Structure Function and Bioinformatics
96. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations
    Zhang, Yan, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China, Wang, Zheng, Hao, Xuezhi, Hu, Xingsheng, Wang, Hongyu, Wang, Yan, Ying, Jianming, Department of Pathology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China, Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China · 2017 · Chinese Journal of Cancer Research
97. EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function
    Sonali Bahl, Hongbo Ling, Nuwan P. N. Acharige, Irene Santos‐Barriopedro, Mary Kay H. Pflum, Edward Seto · 2021 · Cell Death and Disease
98. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
    Debby D. Wang, Lichun Ma, Maria Pik Wong, Victor Ho-Fun Lee, Hong Yan · 2015 · PLoS ONE
99. Current and Future Approaches in the Management of Non–Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs
    Alexios Matikas, Dimitrios Mistriotis, Vassilis Georgoulias, Athanasios Panayotis Kotsakis · 2015 · Clinical Lung Cancer
100. Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation
     Minghui Li, Stephen C. Kales, Ke Ma, Benjamin A. Shoemaker, Juan Crespo-Barreto, Andrew L. Cangelosi, Stanley Lipkowitz, Anna R. Panchenko · 2015 · Cancer Research